These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29150335)

  • 1. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
    Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
    Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
    Cincinelli R; Musso L; Artali R; Guglielmi MB; La Porta I; Melito C; Colelli F; Cardile F; Signorino G; Fucci A; Frusciante M; Pisano C; Dallavalle S
    PLoS One; 2018; 13(10):e0205018. PubMed ID: 30300374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A series of camptothecin prodrugs exhibit HDAC inhibition activity.
    Zhu Q; Yu X; Shen Q; Zhang Q; Su M; Zhou Y; Li J; Chen Y; Lu W
    Bioorg Med Chem; 2018 Sep; 26(16):4706-4715. PubMed ID: 30115492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents.
    Hong S; Shin Y; Jung M; Ha MW; Park Y; Lee YJ; Shin J; Oh KB; Lee SK; Park HG
    Eur J Med Chem; 2015; 96():218-30. PubMed ID: 25884112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
    Dallavalle S; Musso L; Cincinelli R; Darwiche N; Gervasoni S; Vistoli G; Guglielmi MB; La Porta I; Pizzulo M; Modica E; Prosperi F; Signorino G; Colelli F; Cardile F; Fucci A; D'Andrea EL; Riccio A; Pisano C
    Eur J Med Chem; 2022 Jan; 228():113971. PubMed ID: 34772529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
    Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-acting histone deacetylase-topoisomerase I inhibitors.
    Guerrant W; Patil V; Canzoneri JC; Yao LP; Hood R; Oyelere AK
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3283-7. PubMed ID: 23622981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase I inhibitors.
    Cheng P; Zhu L; Guo W; Liu W; Yao J; Dong G; Zhang Y; Zhuang C; Sheng C; Miao Z; Zhang W
    J Enzyme Inhib Med Chem; 2012 Jun; 27(3):437-42. PubMed ID: 21770860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
    Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
    Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
    Wang MJ; Liu YQ; Chang LC; Wang CY; Zhao YL; Zhao XB; Qian K; Nan X; Yang L; Yang XM; Hung HY; Yang JS; Kuo DH; Goto M; Morris-Natschke SL; Pan SL; Teng CM; Kuo SC; Wu TS; Wu YC; Lee KH
    J Med Chem; 2014 Jul; 57(14):6008-18. PubMed ID: 25003995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity.
    Yang XY; Zhao HY; Lei H; Yuan B; Mao S; Xin M; Zhang SQ
    ChemMedChem; 2021 Mar; 16(6):1000-1010. PubMed ID: 33241878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
    Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
    Guo W; Miao Z; Sheng C; Yao J; Liu W; Zhu L; Zhang Y; Cheng P; Dong G; Zhuang C; Zhang W
    Chem Biodivers; 2011 Jul; 8(7):1266-73. PubMed ID: 21766447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psammaplin A analogues with modified disulfide bond targeting histone deacetylases: Synthesis and biological evaluation.
    Jiang Y; Tang Y; Li Y; Liu L; Yue K; Li X; Qiu P; Yin R; Jiang T
    Eur J Med Chem; 2024 Sep; 275():116541. PubMed ID: 38851056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.
    Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W
    J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.